Strategic divestment signals Gerresheimer recently announced the sale of two packaging units to Apax for about €1.5 billion, indicating a potential strategic realignment. This could create opportunities to approach their remaining packaging and drug delivery portfolios with tailored solutions that align with a refocused corporate strategy and debt optimization needs.

Debt refi opportunities Management is focused on refinancing debt and improving cash generation after completing a broad review of compliance and accounting matters. This environment may drive demand for efficiency-enhancing packaging, supply chain digitization, and cost-reducing medical device and packaging solutions.

Regulatory and governance focus External probes and revenue recognition findings have placed emphasis on governance and process integrity. This creates an opening for Gerresheimer to partner on compliant, auditable packaging and device solutions with enhanced traceability, validation, and digital record-keeping that satisfy stringent regulatory requirements.

Interim leadership transition A change in leadership and interim CEO appointment suggests potential openness to strategic pivots and accelerated decisions. Sales teams can engage with senior stakeholders to present rapid-onboarding programs, scalable packaging platforms, and modular drug-delivery systems that support agility during leadership transitions.

Global footprint with local supply With over 40 production sites across 16 countries and a strategy to produce locally for regional markets, Gerresheimer values regional manufacturing resilience. There is an opportunity to offer regionalized packaging and delivery solutions, supply chain visibility tools, and turnkey digital solutions that reduce lead times and bolster local market responsiveness.